[The effects of continuous infusion of landiolol on heart rate changes after neostigmine-atropine administration during recovery from general anesthesia].
BACKGROUND
On reversal of muscle relaxants when neostigmine-atropine mixture is used, heart rate changes occurr. We examined whether landiolol attenuate the initial increases in heart rate after intravenous injections of a neostigmine-atropine mixture.


METHODS
Twenty-four patients were assigned to one of two groups (n=12 each): control group and landiolol group. Anesthesia was induced with propofol and was maintained with isoflurane-nitrous oxide-pentazocine. A mixture of neostigmine 2 mg and atropine 1 mg was injected intravenously over 30s in the control group. In the landiolol group, 0.125 mg x kg)-1) x min(-1) of landiolol for 1 minute was administered immediately after neostigmine-atropine injection. Blood pressure and heart rate were measured noninvasively.


RESULTS
Heart rate was significantly increased after neostigmine-atropine administration compared with that at pre-administration in both groups. At 2 and 3 minutes after neostigmine-atropine administration, heart rate in the landiolol group was significantly lower than that in the control group. The maximum increase in heart rate after the neostigmine-atropine injections was significantly less in the landiolol group than that in the control group. Blood pressure showed no significant changes in both groups during the observation period.


CONCLUSIONS
Landiolol was useful for heart rate control after neostigmine-atropine administration during recovery from general anesthesia.
Nonaka
Akihiko
A
Department of Anesthesia, Yamanashi Prefectural Central Hospital, Yamanashi.
Suzuki
Satomi
S
Abe
Fumiaki
F
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000762:Anesthesia Recovery Period; D000768:Anesthesia, General; D001285:Atropine / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000494:pharmacology*; D009388:Neostigmine / Q000008:administration & dosage* / Q000009:adverse effects; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D009025:Morpholines; D009388:Neostigmine; C077049:landiolol; D001285:Atropine; D014508:Urea